NS Pharma's NS-050/NCNP-03, an antisense oligonucleotide, has been granted rare pediatric disease designation by the FDA for Duchenne muscular dystrophy (DMD) treatment.
Ractigen's RAG-18, an RNA activation agent targeting utrophin, received orphan drug designation for Duchenne and Becker muscular dystrophy, offering development incentives.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.